The approval was based on additional efficacy data from the ACCESS IUS trial. The Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for Liletta ® ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Liletta 52 mg intrauterine device continues to safely ...

IUDs are a highly effective form of birth control, with both hormonal (Mirena, Liletta, Kyleena, and Skyla) and non-hormonal (Paragard) options exceeding 99% effectiveness in preventing unplanned ...

Another day, another way to avoid getting pregnant. This time it’s a new IUD called Liletta, which just received FDA approval for use in the United States. (Of course, it’s already been approved for ...

Actavis plc (NYSE: ACT), a leading global specialty pharmaceutical company, and Medicines360, a nonprofit women's health pharmaceutical company, today announced the approval of LILETTA™ ...

Zoe Reiches got her first IUD this August — a new model with the lilting name Liletta. Reiches, 25 and a human resources specialist in Boston, is now happily set for birth control for at least three ...

Allergan plc AGN and partner Medicines360, a nonprofit global women's health pharmaceutical company, announced that the FDA has accepted a supplemental New Drug Application (sNDA) for its marketed ...

Please provide your email address to receive an email when new articles are posted on . Actavis and Medicines360 announced today that the FDA has granted approval to intrauterine device, Liletta, for ...

Allergan plc, a leading global pharmaceutical company, launched the Liletta + Liletta Patient Commitment Programme, an innovative programme for eligible patients to obtain a second Liletta at no ...

In a taupe-walled exam room at the Women’s Community Clinic in San Francisco, lead clinician Lisa Mihaly plucks a small laminated card from a cabinet. Tethered to the card are three T-shaped IUDs, or ...

Liletta, a hormone-releasing system, was initially approved in February 2015. The system is inserted into the woman’s uterine cavity and should be replaced after 5 years if continued pregnancy ...

Clinician holding an IUD device The expanded approval was supposed by safety and efficacy data from the Phase 3 ACCESS IUS trial (N=1751) in women receiving Liletta. In the trial, Liletta demonstrated ...